We are excited to announce that the Call for Late-Breaking Abstracts for the 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2025) is now open! This is a fantastic opportunity for researchers and scientists to present groundbreaking and cutting-edge research that has emerged after the regular abstract submission deadline. Late-Breaking Abstracts will be showcased at the APPLE 2025 conference, offering a platform for the latest and most innovative developments in the field.

Abstract Submission Period

※The deadline for submissions will not be extended. Please submit abstracts before the deadline.

※No matter the reason, abstract revisions after the submission deadline will not be accepted.

Submission Guidelines

Late-breaking abstracts are intended for research that provides new insights or discoveries with significant relevance to the field. If your research has been completed after the regular abstract submission deadline, and your findings are of high importance or timely significance, we strongly encourage you to submit your late-breaking abstract.

Eligibility Criteria

• Late-breaking abstracts should reflect novel research with results that were not available at the time of the original abstract submission deadline.
• Only research findings that were not published or presented elsewhere before the submission deadline are eligible.
• All submitted abstracts must comply with the APPLE 2025 abstract format.

Abstract Submission

• Submit ONLY ONE abstract per first author, with the exception of co-presenters.

  *The abstract submission should be done by the first author of the abstract.

• Please send the completed Excel file of the Late-Breaking Abstract Submission Form and the graphics-and-tables file to the Congress Secretariat at apple2025@c-linkage.co.jp as email attachments.

• Late-Breaking Abstract
  Submission Form

Important Notes

• The Presenting Author of the abstract must be one of the authors listed in the abstract.
• All presenting authors must have registered and paid to attend the conference.
• Abstracts must be submitted in English.
• Abstracts may not be withdrawn or updated following acceptance notification.

Abstract Format

• Abstract title must not exceed 20 words.

  Capitalize the first letter of each major word, except for articles, prepositions, and conjunctions.

  ※Please ensure that all characters, including spaces, are in half-width format.

• Abstract text must not exceed 300 words (excluding the Title, Author Names, and Affiliations).

  Do not include references to institution names, geographic locations, or funding sources.

  ※Please ensure that all characters, including spaces, are in half-width format.

• An Acceptable Structure of an abstract must consist of the following components:

  Background/Aim: A statement of the hypothesis or research question.

  Methods: An explanation of the study design and experimental methods used.

  Results:
  A concise summary of the major findings of the experiment or study.
  Sufficient data must be provided to permit evaluation by the reviewers and the public to read the abstract.
  Statements such as "The data will be discussed" are not acceptable.

  Conclusion(s): Summary of the overall findings and the importance of the study.

  Graphics and Tables can be submitted as part of an abstract.

  ※ Only one file is allowed per abstract. Combine all graphics and tables into a single JPEG, PNG, or PDF file. The maximum file size is 500 KB.

• Author names and affiliations:

  Up to 15 authors and affiliations may be included on each abstract. All authors must have consented to the abstract submission.

• Presenting authors are responsible for proofreading before submission. No edits will be allowed in submitted abstracts for typing, spelling, or grammatical errors.

Suggested Topics for Abstract Submission are:

• Liver Cancer

  Epidemiology and Surveillance

  Diagnosis and Liver Imaging

  Staging and Prognosis

  Biomarkers

  Molecular Pathogenesis and Pathology

  Treatment: Clinical Trials

  Treatment: Surgical Resection and Transplantation

  Treatment: Transarterial Approach/Percutaneous Ablative Therapy/Radiation Therapy

  Treatment: Systemic Therapy / Targeted Therapy / Immunotherapy

  Treatment: Novel Target or Experimental Therapy

  Cell Biology and Translational Research

  AI

  Miscellaneous

• Viral Hepatitis
• Cirrhosis and Related Complications
• Other Hepatobiliary Diseases

Notification of Acceptance

• The first author/corresponding author will be notified of their acceptance status via email. The first author/corresponding author must inform their co-author(s), if any, of acceptance.
• The Organizing Committee reserves the right to accept or decline any submissions and to select the presentation format.

Abstract Modification or Withdrawal

• The first author can resubmit the Late-Breaking Abstract Submission Form to modify their abstract until the submission deadline.
• Please contact the Congress Secretariat at apple2025@c-linkage.co.jp by the submission deadline if you wish to withdraw your abstract.
• Once you receive the acceptance notification via email, the abstract can no longer be modified or withdrawn.